Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
| العنوان: | Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors |
|---|---|
| المؤلفون: | Stephen A. Graves, Yusuf Menda, David L. Bushnell, Thomas M. O'Dorisio, Kellie L. Bodeker, M. Sue O'Dorisio, Gideon K. D. Zamba, Mark T. Madsen |
| المصدر: | Journal of Nuclear Medicine. 62:1274-1277 |
| بيانات النشر: | Society of Nuclear Medicine, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Combination therapy, business.industry, Phases of clinical research, 030209 endocrinology & metabolism, Neuroendocrine tumors, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, Internal medicine, Radionuclide therapy, Cohort, 90Y-DOTATOC, medicine, Dosimetry, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Bone marrow, business |
| الوصف: | Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding 131I-metaiodobenzylguanidine (131I-MIBG) to PRRT may be advantageous in this regard. Methods: A phase 1 clinical trial was initiated for patients with nonoperable progressive neuroendocrine tumors using a combination of 90Y-DOTATOC plus 131I-MIBG. Treatment cohorts were defined by radiation dose limits to the kidneys and the bone marrow. Subject-specific dosimetry was used to determine the administered activity levels. Results: The first cohort treated subjects to a dose limit of 1,900 cGy to the kidneys and 150 cGy to the marrow. No dose-limiting toxicities were observed. Tumor dosimetry estimates demonstrated an expected dose increase of 34%–83% using combination therapy as opposed to 90Y-DOTATOC PRRT alone. Conclusion: These findings demonstrate the feasibility of using organ dose for a phase 1 escalation design and suggest the safety of using 90Y-DOTATOC and 131I-MIBG. |
| تدمد: | 2159-662X 0161-5505 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::f6f4fd0e157b9387e198ae85a2d7dc57Test https://doi.org/10.2967/jnumed.120.254987Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi...........f6f4fd0e157b9387e198ae85a2d7dc57 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 2159662X 01615505 |
|---|